CamPath-1H (Alemtuzumab)
Campath is indicated for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy. It is also a potentially new treatment for Multiple Sclerosis or MS.
It is currently undergoing trials in the UK, USA, Italy and Croatia to determine whether it can help those with an early form of MS. The drug is a monoclonal antibody designed to target that part of the immune system which is assumed to be harming people with MS.
Campath Side Effects
- Low blood counts
- Nausea and vomiting
- Infection
References
Campath on Chemocare
WARNING:
Campath should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.
As a multiple sclerosis treatment it is currently undergoing trials in the UK, USA, Italy and Croatia to determine whether it can help those with an early form of MS. The drug is a monoclonal antibody designed to target that part of the immune system which is assumed to be harming people with MS (PwMS). Campath’s scientific name is alemtuzumab and it is currently manufactured by ILEX Pharmaceuticals and distributed by Berlex Laboratories. It has been developed for a number of years, and has already been used as a treatment for B-cell chronic lymphocytic leukaemia.
Recent News 14 Sep 2006 As reported on the MS Society Web site, the interim results of a phase II trial show promise. They show that people with MS taking the drug at both high and low doses experiences at least a 75% reduction in the risk of a relapse, compared to those taking Rebif (interferon beta-1a), after more than two years of follow-up
